RecruitingPhase 3NCT05549167
Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)
Studying Juvenile nasopharyngeal angiofibroma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Intervention
- Sirolimus(drug)
- Enrollment
- 117 enrolled
- Eligibility
- 7-18 years · MALE
- Timeline
- 2022 – 2029
Study locations (1)
- Research Institute of Pediatric Hematology, Oncology and Immunology, Moscow, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05549167 on ClinicalTrials.gov